Company profile for Alladapt Immunotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, th...
We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Alladapt Immunotherapeutics, Inc. 611 Santa Cruz Avenue Menlo Park, CA
Telephone
Telephone
650-420-3900
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/11/22/2784744/0/en/Alladapt-Immunotherapeutics-Receives-FDA-Fast-Track-Designation-for-ADP101-for-the-Treatment-of-Mono-and-Multi-Food-Allergies.html

GLOBENEWSWIRE
22 Nov 2023

https://www.globenewswire.com//news-release/2023/11/09/2777583/0/en/Alladapt-Immunotherapeutics-Presents-Phase-1-2-Harmony-Data-Demonstrating-Therapeutic-Potential-and-Safety-of-ADP101-for-the-Treatment-of-Food-Allergy-at-2023-ACAAI-Annual-Meeting.html

GLOBENEWSWIRE
09 Nov 2023

https://www.globenewswire.com/news-release/2023/06/13/2686998/0/en/Alladapt-Immunotherapeutics-Announces-Topline-Pediatric-Data-from-Phase-1-2-Harmony-Study-Evaluating-ADP101-for-the-Treatment-of-Patients-with-Mono-and-Multi-Food-Allergy-as-Presen.html

GLOBENEWSWIRE
13 Jun 2023

https://endpts.com/alladapt-touts-data-on-food-allergy-drug-as-it-preps-for-phiii/

Lei Lei Wu ENDPTS
13 Jun 2023

https://www.globenewswire.com/news-release/2023/05/16/2669796/0/en/Alladapt-Announces-Presentations-at-European-Academy-of-Allergy-and-Clinical-Immunology-EAACI-Congress-2023.html

GLOBENEWSWIRE
16 May 2023

https://www.globenewswire.com/news-release/2023/05/01/2658168/0/en/Alladapt-Appoints-Louise-Peacock-as-Chief-Regulatory-Affairs-and-Quality-Officer.html

GLOBENEWSWIRE
01 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty